during their lifetime (Parsonnet et al., 1991) . Gastric cancer pathogenesis is a complex process involving both host and bacterial genetic factors, which play a role in the development of the inflammation, epithelial transformation, etc. (Wroblewski et al., 2010; Alzahrani et al., 2014) . Many recent studies have focused on the role of single nucleotide polymorphisms (SNP) involved in the gastric carcinogenesis (Wroblewski et al., 2010) , which are selected either from genome-wide association studies or because the geneencoded product is or may be involved in gastric cancer pathogenesis.
The gastrointestinal tract is rich in neuroendocrine cells producing various hormones: G cells produce gastrin, D cells produce somatostatin, enterochromaffin-like (ECL) cells produce histamine and others (Ched et al., 2006) . Histamine-producing ECL cells are located in the oxyntic mucosa of the stomach and have paracrine appearance (Hananson et al., 1986) . Histamine has various biological effects acting via four types of histamine receptors (Hill et al., 1997; de Ersh et al., 2005) ; stimulation of histamine H2 receptor (HRH2) plays a crucial role in the regulation of gastric acid secretion (Hill et al., 1997; Ched et al., 2006) . Histamine has an important role in the process of the gastric mucosa inflammation acting via HRH2, albeit H. pylori infection is the major contributing factor in the development of inflammation (McGowan et al., 1996) .
The HRH2-encoding gene is located on the 5q35.2 chromosome. SNP of the enhancer element of the HRH2 gene promoter rs2067474 results in the transition of -1018 G > A and may be associated with changes of expression of the receptor (Guo et al., 2005) . Currently, only few papers on the association of HRH2 SNP rs2067474 with gastric mucosa atrophy and gastric cancer have been published, in the Japanese population by Arisawa's group Yamada et al., 2012) .
The aim of our study was to determine if there is an association of HRH2 -1018 G > A (rs2067474) genotype with gastric cancer and/or atrophic gastritis in the Latvian (Caucasian) population, which has European ancestry.
MATERIALS AND METHODS

Study design.
Gastric cancer patients (n = 121) from Rîga East Clinical University Hospital (Latvia) with an established diagnosis were invited to participate in the study.
Patients (n = 650) being referred for upper gastrointestinal endoscopy to the outpatient department of Rîga East Clinical University Hospital or Centre of Digestive Diseases "GASTRO" (Latvia) due to dyspeptic symptoms were included in the control group. The following exclusion criteria were used: gastric lymphoma, gastric dysplasia, cancer of the oesophagus, Barrett's oesophagus and history of previous gastric surgery. All patients who participated in the study were Caucasians. All patients were invited to participate in the study during the time period 2010-2014.
A blood sample with EDTA anticoagulant was taken from each patient for DNA extraction with further genotyping. DNA was extracted from whole blood using the phenolchlorophorm method. All control group patients underwent upper gastrointestinal tract endoscopy with further histopathological evaluation of the biopsies.
Upper gastrointestinal tract endoscopy. The upper gastrointestinal tract endoscopy was performed after night-time fasting. Standard biopsy material from each patient was taken during the procedure from at least five different locations in the stomach: two from corpus mucosa (one from the lesser and one from the greater curvature), one from incisura angularis mucosa (from the lesser curvature) and two from antral mucosa (one from the lesser and one from the greater curvature) (Dixon et al., 1996) . Additional biopsies were taken from any columnar-lined mucosa in the oesophagus and sites suspicious for neoplastic lesions in the stomach and oesophagus.
Histopathology. Three experienced expert gastrointestinal pathologists, blinded to any clinical data, separately examined all the biopsies for controls. All histopathological findings were reported separately for each biopsy site from the stomach: corpus mucosa, incisura angularis mucosa and antrum mucosa. The slides were stained with hematoxylineosin, Alcian blue and Giemsa. Metaplastic epithelial changes, H. pylori colonisation and gastric mucosa atrophy were scored using visual analogue scales (0 = absents, 1 = mild, 2 = moderate, 3 = severe), according to the updated Sydney classification system (Dixon et al., 1996) . All results were transformed into the OLGIM and OLGA staging systems (Rugge et al., 2013) .
In case the difference in the evaluation scores of any position by at least of two points was considered significant, all such cases were reassessed by all three pathologists together until consensus agreement was reached.
All histopathological slides from gastric cancer surgery cases were reassessed by two expert gastrointestinal pathologists. The slides were stained with hematoxylin-eosin. Consensus agreement about each case was achieved. Whenever proper morphological material was available (in accordance to WHO standards) (Bosman et al., 2010) , subtyping according to the Lauren classification was done (Lauren, 1965) .
Genotyping of polymorphisms. DNA was extracted by the standard phenol-chloroform method. Genotyping for rs2067474 (-1018 G > A) was performed with the TaqMan Probe-based system (Applied Biosystems Inc., Carlsbad, CA, USA) using a commercially available probe (C_15859301_10) on an automatic sequence detection instrument (Real-Time PCR System, Applied Biosystems Inc., Carlsbad, CA, USA). Reactions were carried out under the standard conditions as recommended by the manufacturer.
Serology. Blood samples for serological evaluation were taken prior to surgery (in gastric cancer patients) and prior to upper gastrointestinal endoscopy (in controls). Blood serum was separated from the whole blood and stored frozen at -80 o C in the laboratory. All serum samples were ana- -11 (15.12.2010) ) approved the study protocol before patient recruitment was started. All the patients signed informed consent forms before the enrolment according to the Helsinki declaration.
RESULTS
The characteristics of both study groups are shown in Table  1 . Male/female ratio, mean age, and positive H. pylori serology ratio were significantly higher in the gastric cancer patients. The AA genotype was not present in the gastric cancer group nor among the control group members. In the control group, the AG genotype was found in 20 patients and GG -in 630. It was in the Hardy-Weinberg equilibrium (p 0.05). The frequency of the A allele in the gastric cancer group was 0.41% and in the control group -1.54%. There was no significant difference comparing genotype ratios between both study groups (p = 0.228). After adjusting for gender, age and H. pylori serology, no significant difference in genotype frequency was identified (OR = 0.236, CI95% = 0.030-1.896, p = 0.176). (Edge et al., 2009) . The only patient with the AG genotype in the cancer group had mixed-type gastric cancer and stage III disease.
The control group was subdivided into two groups according to the OLGIM classification system: one group having an OLGIM 0 stage (n = 485) and the other group having an OLGIM I-IV stage (n = 165). The general characteristics of those groups are shown in the In addition, the control group was subdivided into two groups according to the OLGA stage classification system: one group having the OLGA stage 0 (n = 353) and the other group having the OLGA stage I-IV (n = 297). The general characteristics of those groups are shown in Table 3 . After adjusting for age, H. pylori serology and H. pylori histology, no significant difference was identified in the genotypes (OR = 1.145, CI95% = 0.451-2.906, p = 0.776). Both groups had similar A allele frequencies of 1.42% and 1.68%, respectively, OLGA stage I-IV and OLGA stage 0. All patients (n = 10) with the AG genotype in the OLGA stage I-IV subgroup had the OLGA stage I. There were 233 patients with OLGA stage I, 41 -with stage II, 17 -with stage III and six -with stage IV.
In the control group patients with the GG genotype had an increase of both OLGIM and OLGA stage with age (see Figure 1 and Figure 2 , respectively), respectively r2 = 0.332 (p < 0.001) and r2 = 0.299 (p < 0.001). No significant difference was found in patients with the AG genotype.
Post hoc statistical power estimation (desired significance level 0.05) was done. Statistical power of A allele frequency and gastric cancer was 21.1%.
DISCUSSION
Several reports on the role of HRH2 -1018 G > A (rs2067474) polymorphism in the risk of human disease development are currently available. Many reports are focused on the association of HRH2 -1018 G > A polymorphism and diseases of the central nervous system (Mancama et al., 2002; Garcia-Martin et al., 2008) and breast cancer (Cai et al., 2015) . However, only a few studies have addressed the potential associations to gastric precancerous lesions, i.e. atrophic gastritis Yamada et al., 2012) , and the only study addressing the association to gastric cancer was the one by Arisawa et al. (2012) . In our study, we were unable to identify any significant differences in the distribution of HRH2 -1018 G > A genotype among gastric cancer patients in comparison to patients with no gastric cancer. There was also no difference observed when comparing patients with intact gastric mucosa to patients with atrophic gastritis. In the study of Arisawa there was a significant association of gastric cancer and HRH2 -1018 G > A polymorphism, and A allele presence was considered as a protective factor for gastric cancer . The positive result of the study partially may be explained by the higher frequency of the A allele in the Japanese population.
The HRH2 -1018 A allele frequency in Latvian non-gastric cancer patient group was 1.54% only. That is lower than in the patient sample from Arisawa's study (13.5%) and also lower than in healthy Spanish population (5.0%) (Garcia-Martin et al., 2008) . There are known differences among populations in the A allele frequency, e.g., the 1000 Genomes Project data showed a general frequency in European populations of 4% (ranging from 3.3% in the Iberian population of Spain to 5.6% in Finland) and in Eastern Asians -13.9% (from 9.6% in Japanese from Tokyo to 17% in Han Chinese in Beijing, China) (www.1000genomes.org) (Auton et al., 2015) .
The main limitation of the study was the small statistical power on the post hoc analysis due to a very small frequency of the A allele in the Latvian population. Some other limitations of the study were male/female ratio; mean age and positive H. pylori serology ratio were significantly higher in the gastric cancer patients. For this reason, adjustment for these factors was done, but still no significant difference among genotype distribution was identified. Another limitation was that the control group patients were represented by the population of patients with various symptoms from the upper digestive tract.
In our study, we did not observe any association of HRH2 -1018 G > A polymorphism with different OLGIM and OLGA stages. The A allele frequency was similar in patients with intact gastric mucosa compared to patients with changes of various degrees in gastric mucosa. However, we could identify only a weak correlation of age with OLGA and OLGIM score in non-gastric cancer patients with GG genotype. Even so, one Japanese group published several reports, where a significant association of GG genotype with metaplasia and/or atrophy of gastric mucosa was found in persons older than 60 years Yamada et al., 2012) .
Many publications (Lampiasi et al., 2007; Gricco et al., 2008) are available regarding the role of histamine in the development of gastrointestinal cancers. The SNP of the enhancer element of the HRH2 gene promoter rs2067474 may be associated with changes of expression of the receptor and/or function of HRH2. In experimental models with gastric cancer cell lines, it was found that stimulation of HRH2 stimulates an increase of cAMP production (Ermani et al., 1983) , which in advance stimulates the growth of gastric cancer (Kong et al., 2012) . It was also found that the rs2067474 GG homozygote is associated with CDH1 and DAPK methylation, which is crucial for gastric carcinogenesis (Nomura et al., 2013) . Even so, the current data available do not identify the precise role of HRH2 -1018 G > A (rs2067474) polymorphism in the gastric carcinogenesis.
In conclusion, our findings suggest that the HRH2 -1018 G > A polymorphism (rs2067474) is neither associated with gastric cancer nor the grade of atrophic gastritis in the Latvian (Caucasian) population. The frequency of the A allele in the Latvian (Caucasian) population is extremely different from the Japanese population and is the lowest among European populations. Future epidemiological studies are needed based on a larger sample size in populations with very low A allele frequency, such as the Latvian population, including at least 1500 patients in each group, to determine if the HRH2 -1018 G > A polymorphism (rs2067474) is associated with gastric cancer.
